Raymond James Financial’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.9M Sell
528,550
-145,126
-22% -$5.36M ﹤0.01% 1674
2026
Q2
$26.1M Buy
673,676
+303,961
+82% +$10.6M 0.01% 1370
2026
Q1
$14.2M Sell
369,715
-6,204
-2% -$229K ﹤0.01% 1732
2025
Q4
$13.4M Buy
375,919
+86,522
+30% +$2.43M ﹤0.01% 1740
2025
Q3
$4.16M Buy
289,397
+289,352
+643,004% +$3.43M ﹤0.01% 2595
2025
Q2
$323 Buy
+45
New +$249 ﹤0.01% 6731

Other funds holding COGT

Raymond James Financial's COGT Position: Q3 2026 in Review

Raymond James Financial reduced its Cogent Biosciences (COGT) stake by 22% in Q3 2026, selling an estimated $5.36M and leaving 528,550 shares worth $16.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1674.

Raymond James Financial first reported a position in COGT in Q2 2025 and has held it in 6 quarters since. The position peaked at $26.1M in Q2 2026. 202 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Raymond James Financial held 528,550 shares of Cogent Biosciences worth $16.9M as of Q3 2026.
  • Raymond James Financial sold 145,126 Cogent Biosciences shares in Q3 2026, an estimated $5.36M.
  • Cogent Biosciences made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #1674 holding.
  • Raymond James Financial first reported a position in Cogent Biosciences in Q2 2025 and has held it in 6 quarters since.
  • Raymond James Financial's Cogent Biosciences position peaked at $26.1M in Q2 2026.
  • 202 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.